No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
182 |
4. Check minimum number of eventsNone |
182 |
5. Include endpointsNone |
182 |
6. Filter based on genotype QC (FinnGen only) |
159 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E20-E35
- Name in latin
- Perturbationes adrenogenitales
Similar endpoints
↥List of similar endpoints to
Adrenogenital disorders
based on the number of shared cases.
Similar with more cases:
- Exclusions for E4_PCOS_BROAD
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1321 | 789 | 518 |
| Only index persons | 1074 | 671 | 403 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 53.68 | 48.68 | 61.35 |
| Only index persons | 49.85 | 44.47 | 58.80 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 159 | 97 | 62 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | 51.76 | 46.58 | 59.87 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 171
- Matched controls
- 1710
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E25.9
ICD-10 Finland
Adrenogenital disorder, unspecified
+∞
82.0
72
*
E25.01
ICD-10 Finland
Congenital adrenal hyperplasia
+∞
50.6
46
*
E25.00
ICD-10 Finland
Congenital salt-losing adrenal hyperplasia
+∞
47.1
43
*
105
Kela drug reimbursment
Adrenal cortical hypofunction
+∞
31.2
29
*
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
9.6
27.9
37
48
E25.8
ICD-10 Finland
Other adrenogenital disorders
+∞
25.7
24
*
H02AB09
ATC
hydrocortisone; systemic
26.7
22.7
31
14
H02AA02
ATC
fludrocortisone; oral
50.1
18.7
22
5
A11CC03
ATC
alfacalcidol; systemic
27.8
16.5
22
9
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
27.8
16.5
22
9
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
+∞
15.9
15
*
E25.0
ICD-10 Finland
Congenital adrenogenital disorders associated with enzyme deficiency
+∞
15.9
15
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.6
15.5
44
119
A12AA04
ATC
calcium carbonate; oral
33.3
14.2
18
6
I25.9
ICD-10 Finland
Chronic ischaemic heart disease, unspecified
4.6
14.1
39
103
E27.1
ICD-10 Finland
Primary adrenocortical insufficiency
+∞
13.7
13
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
5.7
13.6
28
57
I20.81
ICD-10 Finland
Other angina pectoris stenosed coronary artery
5.2
11.6
26
57
25502
ICD-8 Finland
Diseases of adrenal glands, Virilismus adrenocorticalis
+∞
11.6
11
*
I25.1
ICD-10 Finland
Atherosclerotic heart disease
3.2
10.9
59
243
ZXE20
NOMESCO Finland
More than three and less than five hours
3.8
10.3
37
117
206
Kela drug reimbursment
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
3.2
10.1
51
201
2552A
ICD-9 Finland
Disorders of adrenal glands, Adrenogenital disorders[SYNDROMA ADRENOGENITALE CONGENITUM]
+∞
9.5
9
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.7
9.2
76
388
ZXE10
NOMESCO Finland
More than one and less than three hours
2.7
9.1
78
406
I21.49
ICD-10 Finland
Acute subendocardial infarction unspecified coronary artery status
4.7
9.0
22
52
WX408
NOMESCO Finland
General anesthesy, balanced
2.7
8.3
58
270
C01DA14
ATC
isosorbide mononitrate; oral
3.0
8.1
43
172
E66.01
ICD-10 Finland
Obesity due to excess calories
3.6
8.1
29
91
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
7.6
8.0
18
26
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
12.7
7.7
13
11
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.6
7.7
64
323
TK800
NOMESCO Finland
Hemodialysis
14.2
7.5
12
9
190
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
83.6
7.5
8
*
E21.3
ICD-10 Finland
Hyperparathyroidism, unspecified
83.6
7.5
8
*
E27.4
ICD-10 Finland
Other and unspecified adrenocortical insufficiency
83.6
7.5
8
*
I25.0
ICD-10 Finland
Atherosclerotic cardiovascular disease, so described
4.3
7.4
20
51
C03CA01
ATC
furosemide; systemic
2.5
7.4
72
391
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.4
7.3
29
97
321
Kela drug reimbursment
Paricalcitol and cinacalcet
+∞
7.3
7
*
213
Kela drug reimbursment
Fat metabolism disorder associated with chronic coronary artery disease
3.7
7.3
25
76
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.8
7.3
24
71
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
21.1
7.2
10
5
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
2.6
7.2
53
252
N03AX16
ATC
[U] pregabalin
2.6
7.0
49
226
C08CA02
ATC
felodipine; oral
3.5
6.9
26
84
C07AB02
ATC
metoprolol; systemic
2.6
6.9
49
228
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
4.4
6.8
18
45
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.0
6.5
31
116
V03AE01
ATC
polystyrene sulfonate; oral
15.1
6.5
10
7
N18.8
ICD-10 Finland
Other chronic renal failure
8.7
6.5
13
16
ZXD10
NOMESCO Finland
Scheduled procedure
2.3
6.5
75
434
Z49.1
ICD-10 Finland
Extracorporeal dialysis
18.9
6.3
9
5
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.8
6.3
36
149
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.6
6.3
41
182
196
Kela drug reimbursment
Paricalcitol and cinacalcet
+∞
6.3
6
*
E27.0
ICD-10 Finland
Other adrenocortical overactivity
+∞
6.3
6
*
SPAT1262
SPAT
Handing over of treatment supplies
2.7
6.1
37
158
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.5
6.1
45
212
I21.99
ICD-10 Finland
Myocardial infarction (acute) UNS unspecified coronary artery status
7.7
6.0
13
18
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
24
0
+∞
25.66
8.9
0.0
64.29
—
nmol/l
—
24
0
25
11
26.31
18.36
4.3
1.5
123.00
24.15
ng/l
2.36
25
11
39
106
4.47
13.57
7.6
3.5
159.55
72.37
ng/l
2.04
29
91
21
36
6.51
12.12
2.8
1.2
7.33
7.61
u/l
0.03
12
30
19
40
5.22
8.82
3.3
2.4
2.08
2.00
index
0.02
13
23
112
709
2.68
8.60
18.5
6.6
1.22
1.21
mmol/l
0.34
98
605
25
69
4.07
8.37
2.2
1.2
17.00
24.07
iu/l
0.46
16
63
37
155
2.77
6.34
5.7
3.3
5.93
5.61
kpa
0.93
37
150
32
134
2.71
5.46
3.6
3.0
5.07
4.51
kpa
0.79
32
129
47
242
2.30
5.17
1.8
1.7
1056.17
1180.14
nmol/l
0.30
41
178
22
81
2.97
4.73
2.0
1.7
—
—
—
0
0
46
244
2.21
4.67
2.7
2.0
—
—
—
0
0
34
163
2.36
4.35
2.4
1.8
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
12
25
5.08
4.27
3.1
2.3
0.35
0.36
iu/ml
—
6
14
35
175
2.26
4.06
2.3
1.7
—
—
—
0
0
65
415
1.91
3.91
5.8
3.1
0.25
0.46
e6/l
0.67
52
290
14
38
3.92
3.90
8.8
6.1
1.46
5.75
ratio
—
8
17
60
383
1.87
3.55
2.7
2.2
2.87
3.01
mg/l
0.13
55
328
107
821
1.81
3.42
8.1
4.6
7.09
6.51
mmol/l
1.56
101
768
26
124
2.29
3.35
3.4
2.9
27.32
29.71
u/l
0.29
19
106
9
21
4.46
3.04
11.0
2.1
11.02
6.33
pmol/l
—
9
21
11
34
3.39
2.78
1.6
2.0
—
—
—
0
0
78
592
1.58
2.26
2.7
2.2
93.21
95.64
pmol/l
0.20
45
312
5
9
5.68
2.23
4.6
5.8
279.60
500.22
mg
—
5
9
9
30
3.11
2.18
1.7
1.4
—
—
—
0
0
6
14
4.40
2.17
1.0
1.3
—
—
—
0
0
101
820
1.57
2.15
13.0
10.1
4.28
4.11
e9/l
0.36
86
715
10
37
2.81
2.11
1.4
1.4
—
—
—
0
0
10
38
2.73
2.04
1.6
1.4
—
—
—
0
0
39
255
1.69
2.03
6.6
3.5
40.48
202.49
ng/l
0.83
31
197
46
315
1.63
2.01
1.9
1.9
0.79
1.40
mg/l
1.13
38
245
93
752
1.52
1.94
7.5
6.2
10.12
11.18
umol/l
0.79
93
712
138
1226
1.65
1.82
8.2
6.1
39.51
39.10
mmol/mol
0.19
133
1138
8
29
2.84
1.81
1.4
1.4
—
—
—
0
0
24
141
1.82
1.80
6.3
3.5
—
—
—
0
0
32
205
1.69
1.79
2.2
2.1
29.59
29.23
s
0.18
32
199
67
515
1.49
1.74
6.8
3.4
2.33
2.36
mmol/l
0.74
62
469
55
407
1.52
1.70
1.9
1.7
23.37
21.72
nmol/l
0.26
50
336
15
77
2.04
1.65
12.5
8.0
24.29
24.23
mmol/l
0.03
15
77
26
162
1.71
1.61
9.9
6.1
0.41
0.72
mmol/l
0.17
21
128
7
26
2.76
1.60
1.9
1.3
—
—
—
0
0
6
20
3.07
1.59
1.0
1.1
—
—
—
0
0
54
413
1.45
1.39
6.1
4.1
23.81
10.94
mg/mmol
0.83
39
264
35
245
1.54
1.38
4.9
3.0
0.83
0.83
e6/l
0.00
17
117
6
24
2.55
1.31
1.5
1.4
—
—
—
0
0
6
24
2.55
1.31
1.5
1.4
—
—
—
0
0
8
34
2.42
1.31
1.5
1.2
—
—
—
0
0
10
48
2.15
1.30
8.3
3.2
0.00
0.00
g/l
—
10
42
33
233
1.52
1.26
5.1
3.2
5.01
3.26
e6/l
0.31
14
107
15
88
1.77
1.15
4.0
3.5
124.60
128.35
g/l
0.21
15
83
10
52
1.98
1.08
8.3
3.5
0.00
0.98
g/l
—
10
47
115
1029
1.36
1.07
5.7
4.3
15.21
11.87
mm/h
1.46
109
935
67
554
1.34
1.06
2.0
2.0
1.36
1.35
mmol/l
0.07
61
465
27
192
1.48
1.00
10.1
5.9
103.33
103.91
mmol/l
0.21
27
192
13
78
1.72
0.94
2.2
1.2
—
—
—
0
0
6
27
2.27
0.94
1.7
1.2
—
—
—
0
0
15
95
1.63
0.91
2.2
2.4
74.37
66.48
ml/min/173m2
—
8
42
6
32
1.91
0.82
1.5
1.4
—
—
—
0
0
119
1090
1.30
0.82
5.4
4.3
14.91
14.82
pmol/l
0.17
114
978
0
25
0.00
0.79
0.0
1.2
—
—
—
0
0
7
38
1.88
0.74
2.0
1.2
—
12.79
—
0
9
9
58
1.58
0.71
1.2
1.6
—
—
—
0
0
7
42
1.69
0.69
2.1
1.6
—
—
—
0
0
5
28
1.81
0.66
1.0
1.3
—
—
—
0
0
16
112
1.47
0.66
2.2
1.6
—
—
—
0
0
9
137
0.64
0.63
3.2
4.7
2.96
39.52
ug/l
—
9
120
14
195
0.69
0.60
1.5
2.3
—
—
—
0
0
45
381
1.25
0.57
1.6
1.3
0.95
1.59
u/ml
0.49
15
100
8
55
1.48
0.57
1.3
1.2
—
7.32
—
0
5
8
55
1.48
0.57
3.4
2.1
—
—
—
0
0
134
1270
1.25
0.55
28.3
15.4
77.07
82.43
ml/min/173m2
1.40
128
1180
101
931
1.21
0.55
3.6
3.2
45.47
43.94
u/l
0.09
95
879
59
517
1.22
0.54
7.5
4.1
34.77
46.41
ng/l
0.55
47
373
28
225
1.29
0.54
1.3
1.3
1.36
9.75
u/ml
—
10
83
6
40
1.52
0.52
1.5
1.3
—
—
—
0
0
12
85
1.44
0.48
1.0
1.0
—
—
—
0
0
16
208
0.75
0.47
1.6
2.5
—
—
—
0
0
7
50
1.42
0.45
1.4
1.3
—
—
—
0
0
5
32
1.58
0.42
1.6
1.3
—
—
—
0
0
98
915
1.17
0.42
3.6
3.4
—
—
—
0
0
8
59
1.37
0.41
3.4
2.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.2
—
9.60
—
0
15
133
1274
1.20
0.40
6.7
5.4
2.06
1.94
mu/l
0.46
128
1167
0
18
0.00
0.40
0.0
1.3
—
222.11
—
0
18
6
42
1.44
0.36
2.3
1.6
—
—
—
0
0
47
419
1.17
0.35
5.4
3.4
0.00
0.00
estimate
-0.00
25
124
36
314
1.19
0.35
1.8
1.7
—
—
—
0
0
83
775
1.14
0.33
5.3
4.1
0.00
0.00
estimate
-0.00
28
162
6
47
1.29
0.32
3.2
2.3
—
—
—
0
0
12
153
0.77
0.32
13.3
7.6
—
—
—
0
0
7
54
1.31
0.31
1.3
1.3
—
—
—
0
0
29
254
1.17
0.27
1.4
1.3
31.88
34.11
iu/ml
—
6
71
15
123
1.24
0.26
1.5
2.3
—
—
—
0
0
22
191
1.17
0.23
2.4
3.3
0.79
0.85
ug/l
0.11
16
124
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
2.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.8
—
13.61
—
0
13
133
1296
1.12
0.20
5.9
4.9
4.39
4.58
mmol/l
1.36
128
1203
28
251
1.14
0.20
3.5
4.8
26.85
21.85
%
0.66
14
133
6
50
1.21
0.20
1.7
1.2
—
—
—
0
0
126
1228
1.10
0.18
4.9
4.1
1.44
1.23
mmol/l
2.32
119
1126
135
1320
1.11
0.17
6.6
5.5
2.52
2.67
mmol/l
1.34
130
1216
68
648
1.08
0.16
3.9
2.7
—
—
estimate
—
0
0
12
102
1.19
0.15
1.5
2.2
—
—
—
0
0
15
170
0.87
0.14
5.9
4.6
35.93
31.47
%
1.09
15
103
81
783
1.07
0.12
5.4
4.2
0.00
9.72
estimate
0.50
28
167
46
437
1.07
0.11
4.7
4.4
0.00
0.01
estimate
0.50
24
146
81
787
1.06
0.10
5.4
4.2
0.00
0.00
estimate
-0.00
28
152
5
46
1.09
0.09
2.2
1.4
—
—
—
0
0
131
1290
1.07
0.09
5.8
4.8
1.43
1.47
mmol/l
0.42
124
1188
13
116
1.13
0.09
1.4
1.5
—
—
—
0
0
5
47
1.07
0.09
1.0
1.3
—
—
—
0
0
5
48
1.04
0.09
3.2
3.9
20.40
4041.56
u/ml
—
5
43
37
352
1.07
0.09
3.9
4.3
1.01
1.02
kg/l
1.59
27
230
36
345
1.06
0.06
3.3
2.2
—
—
—
0
0
59
578
1.03
0.04
5.4
4.1
0.00
0.02
estimate
0.50
24
130
138
1372
1.03
0.02
30.8
15.8
26.36
24.06
mg/l
0.34
120
1133
21
217
0.96
0.01
2.0
1.5
—
—
—
0
0
14
134
1.05
0.00
1.7
1.9
3.06
3.40
ratio
—
9
106
128
1278
1.01
0.00
7.2
4.9
5.93
5.86
mmol/l
0.21
123
1163
0
7
0.00
-0.00
0.0
1.0
—
0.28
—
0
7
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.2
—
9.72
—
0
6
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
33.73
—
0
7
0
6
0.00
-0.00
0.0
3.2
—
4.60
—
0
6
0
8
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.6
—
40.98
—
0
5
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
5
49
1.02
-0.00
1.0
1.2
—
—
—
0
0
7
76
0.92
-0.00
1.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
4.3
—
62.33
—
0
6
0
8
0.00
-0.00
0.0
1.5
—
13.88
—
0
8
5
50
1.00
-0.00
1.8
1.5
—
0.00
—
0
7
0
9
0.00
-0.00
0.0
2.4
—
—
—
0
0
5
52
0.96
-0.00
4.8
1.5
2.53
3.08
mg/l
—
5
36
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_ADRENOGEN and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_ADRENOGEN | 2.292 [1.79, 2.93] | < 0.001 |
| Birth year | 0.995 [0.99, 1.0] | 0.259 |
During the follow-up period (1.1.1998 — 31.12.2019), 185 out of 572 females with E4_ADRENOGEN died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_ADRENOGEN | 2.783 [1.92, 4.04] | < 0.001 |
| Birth year | 0.984 [0.97, 0.99] | < 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 182 out of 401 males with E4_ADRENOGEN died.
Mortality risk
Mortality risk for people of age
years, who have E4_ADRENOGEN.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.204% | 0.453% |
| 5 | 1.287% | 2.978% |
| 10 | 3.461% | 7.181% |
| 15 | 6.431% | 13.75% |
| 20 | 11.168% | 22.495% |
Relationships between endpoints
↥Index endpoint: E4_ADRENOGEN – Adrenogenital disorders
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data